Header

UZH-Logo

Maintenance Infos

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life


Planas, R; Martin, R; Sospedra, M (2014). Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Related Outcome Measures, 5:25-33.

Abstract

Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of the brain caused by the John Cunningham virus, jeopardized this efficacious treatment from the beginning. Eight years after licensing of natalizumab, long-term studies confirm the considerable and sustained efficacy of natalizumab, although the PML complication still threatens one of the most successful treatments available for RRMS. During these years, considerable progress has been made in identification of risk factors that allow more effective management of PML risk. In addition, long-term studies to define better when to start or stop treatment and to optimize treatment strategies after cessation of natalizumab are ongoing, and hopefully will improve management and will allow natalizumab to remain as a valuable therapeutic option for patients with highly active RRMS.

Abstract

Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of the brain caused by the John Cunningham virus, jeopardized this efficacious treatment from the beginning. Eight years after licensing of natalizumab, long-term studies confirm the considerable and sustained efficacy of natalizumab, although the PML complication still threatens one of the most successful treatments available for RRMS. During these years, considerable progress has been made in identification of risk factors that allow more effective management of PML risk. In addition, long-term studies to define better when to start or stop treatment and to optimize treatment strategies after cessation of natalizumab are ongoing, and hopefully will improve management and will allow natalizumab to remain as a valuable therapeutic option for patients with highly active RRMS.

Statistics

Altmetrics

Downloads

76 downloads since deposited on 20 May 2014
23 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:4 April 2014
Deposited On:20 May 2014 12:27
Last Modified:12 Aug 2017 00:11
Publisher:Dove Medical Press
ISSN:1179-271X
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.2147/PROM.S41768
PubMed ID:24741337

Download

Download PDF  'Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life'.
Preview
Content: Published Version
Filetype: PDF
Size: 243kB
View at publisher